Clinical trials: Hematopoietic/Lymphoid Cancer
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain.
- Trial name
- NCT05506982
- Testing
- Psilocybin, Psychotherapy, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Hematopoietic and Lymphoid Cell Neoplasm
Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors
This project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell…
- Trial name
- NCT04892823
- Testing
- Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Medical College of Wisconsin
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has a has a genetic change called NF1 mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439318
- Testing
- Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
This phase I/II trial studies the side effects and the best dose of inotuzumab ozogamicin when given together with fludarabine phosphate, bendamustine hydrochloride, and rituximab before donor stem cell transplant in treating…
- Trial name
- NCT01664910
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Community-Based Physical Activity Intervention for Underserved Cancer Survivors
This clinical trial evaluates a community-based physical activity program for underserved cancer survivors. Cancer and its treatment significantly influence physical, psychosocial, and cognitive functioning.
- Trial name
- NCT06206863
- Testing
- Exercise Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Hematologic Malignancies
Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation
This is a randomized trial for patients undergoing hematopoietic progenitor cell transplantation (HPCT) from an unrelated donor.
- Trial name
- NCT01217723
- Testing
- Anti-Thymocyte Globulin (Rabbit), Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)
- Where
- 10 sites in Canada
- Volunteers
- 198 people
- Sponsor
- McMaster University
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors.
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT04593277
- Testing
- Internet Mobile Technology, Internet-Based Intervention, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 549 people
- Sponsor
- Fred Hutchinson Cancer Center
Childhood Langerhans Cell Histiocytosis, Fanconi Anemia
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma
- Trial name
- NCT00084695
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Lymphoma, Small Intestine Cancer
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing.
- Trial name
- NCT00561418
- Testing
- vorinostat, Correlative studies
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Lung Non-Small Cell Carcinoma
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
This trial evaluates the risk of chemotherapy toxicity in older patients with blood cancer or non-small cell lung cancer. The purpose of this study is to describe a patient's wellness before and after chemotherapy treatment.
- Trial name
- NCT05106374
- Testing
- Biospecimen Collection, Cognitive Assessment, Physical Performance Testing
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lymphoma
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Interferon-alfa may interfere with the growth of cancer cells. Giving interferon-alfa following chemotherapy and peripheral stem cell transplantation may be an effective treatment for Hodgkin's disease or non-Hodgkin's…
- Trial name
- NCT00003924
- Testing
- recombinant interferon alfa
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 360 people
- Sponsor
- Lymphoma Study Association
Breast Carcinoma, Esophageal Carcinoma
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself.
- Conditions
- Breast Carcinoma, Esophageal Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma
- Trial name
- NCT00991094
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancies, Myelogenous Leukemia
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.
- Conditions
- Hematologic Malignancies, Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00144703
- Testing
- Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Dana-Farber Cancer Institute
Hematopoietic and Lymphoid System Neoplasm, Lymphedema
Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study
This clinical trial studies how well new adhesive-based sensors that stick to the skin (transcutaneous) work in detecting cancer-related long-term arm swelling (lymphedema).
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Lymphedema, Malignant Solid Neoplasm
- Trial name
- NCT06305884
- Testing
- Bioelectric Impedance Analysis, Exercise, Photoplethysmography
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Multiple Myeloma, Lymphoma
Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor
Primary Objective: A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients receiving a non-myeloablative allogeneic SCT from a matched sibling donor, with fludarabine and low-dose…
- Conditions
- Multiple Myeloma, Lymphoma, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
- Trial name
- NCT00304720
- Testing
- Tacrolimus and MMF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Colorado Blood Cancer Institute
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT01744223
- Testing
- BPX-501 dose 1, Rimiducid, BPX-501 dose 2
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Bellicum Pharmaceuticals
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of bortezomib when given together with fludarabine with or without rituximab in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma or…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT00068315
- Testing
- bortezomib, fludarabine phosphate, rituximab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07216443
- Testing
- Orca-T
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Orca Biosystems, Inc.
Myeloproliferative Disorders, Acute Myelogenous Leukemia
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
The are a variety of cancerous diseases of the blood and bone marrow that can be potentially cured by bone marrow transplantation (BMT).
- Conditions
- Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00003838
- Testing
- T-cell replete PBPC allograft, Methotrexate, Cyclosporine
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)